Qiagen (NYSE:QGEN) Updates FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.140- for the period, compared to the consensus earnings per share estimate of 2.100. The company issued revenue guidance of -.

Qiagen Trading Up 3.3 %

Shares of QGEN stock opened at $43.73 on Tuesday. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $9.98 billion, a P/E ratio of 29.32, a P/E/G ratio of 3.49 and a beta of 0.42. The stock has a 50-day simple moving average of $42.92 and a 200 day simple moving average of $43.64.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm’s revenue was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 earnings per share. On average, sell-side analysts expect that Qiagen will post 2.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus decreased their price objective on shares of Qiagen from $55.00 to $45.00 and set a hold rating for the company in a research note on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $50.95.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.